Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of IV Peramivir vs Oral Oseltamivir in Pediatric Acute Uncomplicated Influenza
2021-001018-13Phase 3
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peramivir in influenza (2 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoints: Adverse events and Pharmacokinetics of peramivir.
02
Drugs
peramivir
03
Conditions
influenza
Beyond the preview
Go deeper on 2021-001018-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001018-13.